Orion Corporation Streamlines Operations Amid Research Expansion
Orion Corporation is strategically transitioning its research and development activities while establishing a new center in the UK aimed at advancing biological medicines. This move marks a critical point in the company’s evolution, which has a rich history of over one hundred years in enhancing well-being through innovative health solutions.
New R&D Center in Cambridge, UK
Announced on a recent date in March, the new research center will be located in Cambridge, UK. This facility will focus on developing biological and large-molecule therapies, which are key areas in modern medicine. It aligns with Orion’s commitment to pushing the boundaries of pharmacological science and addressing the growing demand for advanced medical treatments.
Conclusion of Statutory Negotiations
The statutory negotiations concerning Orion’s Protein and Antibody Engineering & Characterization unit in Turku have concluded successfully. By wrapping up these discussions ahead of schedule on April 7, the company has decided to streamline operations, aiming for efficiency while securing new roles for many of the affected employees.
Employee Transition Support
As a part of this transition, Orion has proactively facilitated the placement of many staff members into new positions within the company. Only a handful of roles, fewer than ten, will see a reduction. This empathetic approach underscores Orion's dedication to its workforce and their professional development.
Impact of R&D Department Changes
The transformation of the R&D department intends not just to optimize current resources but to funnel efforts into more promising therapies that align with Orion’s business objectives. Through innovation and strategic planning, Orion is reinforcing its position as a leader in the pharmaceutical industry.
Focus on Core Therapy Areas
Orion’s primary R&D focuses on oncology and pain management, areas that are increasingly crucial in today’s healthcare landscape. Proprietary products developed by the company aim to treat serious conditions, including cancer and neurological disorders, further solidifying Orion's commitment to improving patient outcomes.
About Orion Corporation
Orion Corporation is a renowned Nordic pharmaceutical firm, dedicated to the development and marketing of both human and veterinary medicines, and active pharmaceutical ingredients. This commitment to healthcare solutions has positioned Orion as a trusted name among healthcare professionals and consumers alike.
Frequently Asked Questions
What is the significant change at Orion Corporation?
Orion Corporation is concluding its Protein and Antibody Engineering & Characterization unit to enhance its operational efficiency and focus on new R&D initiatives in the UK.
Where is the new R&D center located?
The new research and development center is situated in Cambridge, UK, specializing in biological medicines.
How many employees will be affected by the changes?
Fewer than ten employees from the Turku unit will face reductions, while many others are being offered new roles within the company.
What are Orion’s core areas of research?
Orion's primary research focuses include oncology and pain management, aiming to develop innovative therapies for these critical health issues.
How has Orion Corporation performed financially?
In the previous fiscal year, Orion's net sales reached EUR 1,542 million, showcasing its robust market position and the commitment of its approximately 3,700 employees worldwide.
